carvedilol has been researched along with Primary Peritonitis in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol (CVL) is an α-, β-blocker used to treat high blood pressure and congestive heart failure; however, some benefits beyond decreased blood pressure were observed clinically, suggesting the potential anti-inflammatory activity of CVL." | 1.48 | Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. ( Chen, A; Cheng, CC; Cheng, SM; Hua, KF; Li, LH; Lin, WY; Rao, YK; Wong, WT; Yang, SP, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, WT | 1 |
| Li, LH | 1 |
| Rao, YK | 1 |
| Yang, SP | 1 |
| Cheng, SM | 1 |
| Lin, WY | 1 |
| Cheng, CC | 1 |
| Chen, A | 1 |
| Hua, KF | 1 |
1 other study available for carvedilol and Primary Peritonitis
| Article | Year |
|---|---|
Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome.
Topics: Adrenergic beta-Antagonists; Animals; Autophagy; Carvedilol; Cell Line; Cytokines; Disease Models, A | 2018 |